Breaking News Instant updates and real-time market news.

BCC

Boise Cascade

$29.35

0.4 (1.38%)

, CAT

Caterpillar

$106.59

-0.73 (-0.68%)

07:19
07/22/17
07/22
07:19
07/22/17
07:19

Week in review: How Trump's policies moved stocks

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Trump and his administration with this weekly recap compiled by The Fly: 1. MADE IN AMERICA: President Donald Trump launched "Made in America" week on Monday, showcasing products made in all 50 states. Among the companies participating in this initiative are Boise Cascade (BCC), Caterpillar (CAT), Campbell (CPB), and Steinway (LVB). On Thursday, the CEOs of Corning (GLW), Merck (MRK), and Pfizer (PFE) were welcomed to the White House by President Trump to announce collaborations they say have enabled the modernization of pharmaceutical packaging. As a result of the partnership, Corning is making an initial investment of $500M and creating 1,000 new U.S. jobs as the first part of a planned investment of $4B, the company stated. 2. AMAZON: Speaking in the White House on Monday, the President said, "we need to begin cracking down on the predatory online sales of foreign goods." Although Trump did not name any companies, he did refer to the destruction of American brick and mortar retail sales, saying that "online predatory sales" are "killing shoppers and killing shopping centers." Shares of Amazon (AMZN) dropped following his comments. 3. HEALTH CARE BILL: Also on Monday, President Trump tweeted, "Republicans should just REPEAL failing ObamaCare now & work on a new Healthcare Plan that will start from a clean slate. Dems will join in!" Publicly traded companies in the health insurance space include Aetna (AET), Anthem (ANTM), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG). 4. STEEL TARIFFS: Following a dinner with steel participants last week, Morgan Stanley analyst Evan Kurtz said he is more bullish on second half 2017 steel pricing. The takeaways were that imports are likely to dip significantly in September and October due to traders not wanting to take the risk of being an "import of record" with the threat of tariffs. Further, the analyst said inventories are low, so even with stable demand, the market could get tight, the analyst wrote. Kurtz recommended buying Overweight rated U.S. Steel (X), Steel Dynamics (STLD) and Nucor (NUE). Imposing steel tariffs in the name of national security has been a focus for President Donald Trump since he took office. 5. MEDICARE: On Thursday, The Wall Street Journal reported that hospitals are preparing to fight against a Trump administration proposal that would cut a subsidy which Medicare gives to certain hospitals, including rural and cancer hospitals, to purchase and administer pharmaceuticals to patients in an effort to serve the uninsured. The American Hospital Association and industry executives argue the cut would negatively affect many hospitals eligible for the subsidy as they rely on the payments to assist in financing operations. Publicly traded companies in the hospital space include Community Health (CYH), HCA Holdings (HCA), LifePoint (LPNT), Tenet (THC) and Universal Health (UHS). "Week in Review" is The Fly's weekly recap of its recurring series of "Trump Effect" exclusive stories.

BCC

Boise Cascade

$29.35

0.4 (1.38%)

CAT

Caterpillar

$106.59

-0.73 (-0.68%)

CPB

Campbell Soup

$52.00

0.08 (0.15%)

LVB

Steinway Musical

$0.00

(0.00%)

GLW

Corning

$31.85

0.14 (0.44%)

MRK

Merck

$62.63

-0.31 (-0.49%)

PFE

Pfizer

$33.48

-0.06 (-0.18%)

AMZN

Amazon.com

$1,025.67

-3.03 (-0.29%)

AET

Aetna

$156.31

0.58 (0.37%)

ANTM

Anthem

$190.65

-0.04 (-0.02%)

CNC

Centene

$84.73

-0.67 (-0.78%)

CI

Cigna

$174.23

-0.26 (-0.15%)

HNT

Health Net

$0.00

(0.00%)

HUM

Humana

$235.92

0.09 (0.04%)

MOH

Molina Healthcare

$71.15

-0.9 (-1.25%)

UNH

UnitedHealth

$191.78

0.28 (0.15%)

WCG

WellCare

$183.87

0.1 (0.05%)

X

U.S. Steel

$23.68

-0.47 (-1.95%)

STLD

Steel Dynamics

$37.51

-0.18 (-0.48%)

NUE

Nucor

$60.23

0.31 (0.52%)

CYH

Community Health

$9.27

0.01 (0.11%)

HCA

HCA Healthcare

$85.73

-0.03 (-0.03%)

LPNT

LifePoint

$65.35

-0.15 (-0.23%)

THC

Tenet

$20.65

-0.02 (-0.10%)

UHS

Universal Health

$124.42

-0.58 (-0.46%)

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 26

    Jul

  • 26

    Jul

  • 26

    Jul

  • 26

    Jul

  • 27

    Jul

  • 27

    Jul

  • 28

    Jul

  • 30

    Jul

  • 01

    Aug

  • 01

    Aug

  • 02

    Aug

  • 02

    Aug

  • 02

    Aug

  • 02

    Aug

  • 03

    Aug

  • 03

    Aug

  • 04

    Aug

  • 04

    Aug

  • 08

    Aug

  • 14

    Aug

  • 23

    Aug

  • 27

    Aug

  • 22

    Sep

  • 26

    Sep

  • 27

    Sep

BCC Boise Cascade
$29.35

0.4 (1.38%)

09/22/16
GSCO
09/22/16
INITIATION
Target $34
GSCO
Buy
Boise Cascade initiated with a Buy at Goldman
Goldman analyst Brian Maguire initiated Boise Cascade with a Buy and a $34 price target. The analyst expects a recovery in housing to benefit Boise's volume growth, operating leverage, and pricing in key products.
10/25/16
GSCO
10/25/16
DOWNGRADE
GSCO
Neutral
Boise Cascade downgraded to Neutral from Buy at Goldman
Goldman analyst Brian Maguire downgraded Boise Cascade to Neutral and lowered his price target to $25 from $34 following the weak Q3 report and outlook. The analyst sees too many headwinds continuing at least until Q1 2017 and said the company has not demonstrated the expected leverage to better housing starts.
04/04/17
BOFA
04/04/17
UPGRADE
Target $34
BOFA
Buy
Boise Cascade upgraded to Buy on positive wood product trends at BofA/Merrill
BofA/Merrill analyst George Staphos upgraded Boise Cascade to Buy from Neutral and raised its price target to $34 from $32 saying higher wood product prices and sequential improvement in earnings and valuation should act as a catalyst for shares. The analyst raised his wood price forecasts for 2017 above guidance given recent pricing trends and expectations for increased operating rates with continued improvement in the housing market.
02/08/17
VERT
02/08/17
NO CHANGE
VERT
Lumber prices surged early this week, says Vertical Research
Vertical Research analyst Chip Dillon said trade publisher Random Lengths reported that lumber prices in North America surged early this week, tacking onto the $11 per thousand board feet, MBF, or 3%, rise seen in its lumber composite last week. The two-day increase in the RL Lumber composite this week has been $13/MBF, equal to a further 3.6% lift, meaning that average lumber prices across North America are up nearly 7% in 7 business days, with the RL Lumber Composite up to $379/MBF versus $355 on January 27. The analyst said this could indicate a strong season, which would benefit Boise Cascade (BCC), Louisiana-Pacific (LPX) and OSB companies.
CAT Caterpillar
$106.59

-0.73 (-0.68%)

06/22/17
WELS
06/22/17
NO CHANGE
WELS
Earthmoving market trends positive, says Wells Fargo
After speaking with 20 "U.S. earthmoving market participants," including Caterpillar (CAT) and Deere (DE), Wells Fargo says that the market appears to be "tightening." Wells says that activity in "most regions" showed "broad-based improvement" through Q2. Wells adds that manufacturers seem to have trouble keeping up with demand. Wells says its checks bode well for Caterpillar, Deere, Cummins (CMI), Eaton (ETN) and Parker-Hannifin (PH). It keeps Outperform rating on Caterpillar and Cummins.
06/23/17
DBAB
06/23/17
DOWNGRADE
Target $106
DBAB
Hold
Caterpillar downgraded to Hold on rising expectations at Deutsche Bank
Deutsche Bank analyst Nicole DeBlase downgraded Caterpillar to Hold from Buy telling investors risks are skewed to the downside as consensus estimates have risen and the recovery in mining A/M and incremental cross-cycle margin improvement are reflected in expectations. DeBlase expects Caterpillar to deliver another substantial earnings beat in Q2 but said the scope of earnings revisions for the second half have diminished. As a result, the analyst sees risk of multiple contraction and lowered Caterpillar's price target to $106 from $121.
06/23/17
06/23/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Caterpillar (CAT) downgraded to Hold from Buy at Deutsche Bank with analyst Nicole DeBlase saying risks are skewed to the downside as consensus estimates have risen and the recovery in mining A/M and incremental cross-cycle margin improvement are reflected in expectations. 2. Hain Celestial (HAIN) downgraded to Neutral from Overweight at JPMorgan with analyst Ken Goldman saying fundamentals have worsened more than feared and guidance seems "slightly" optimistic. 3. Baker Hughes (BHI) downgraded to Hold from Buy at Tudor Pickering. 4. Tanger Factory (SKT) downgraded to Underperform from Neutral at BofA/Merrill with analyst Craig Schmidt citing increased concerns about the moderate outlet space. 5. EnerNOC (ENOC) was downgraded to Market Perform from Outperform at Raymond James and to Neutral from Outperform at Baird. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/28/17
FBCO
06/28/17
NO CHANGE
Target $123
FBCO
Outperform
Caterpillar 2017 estimates raised after dealer survey at Credit Suisse
After conducting a survey of Caterpillar dealers, Credit Suisse analyst Jamie Cook noted that U.S. dealers indicated that first quarter strength continued well into the end of the second quarter. Meanwhile, European demand is up in the single digit percentage range and Asia Pacific is "on fire," added Cook, who believes Caterpillar is set up well to raise estimates again with its Q2 report. The analyst, who raised his estimates for Caterpillar, keeps an Outperform rating and $123 price target on the shares.
CPB Campbell Soup
$52.00

0.08 (0.15%)

03/21/17
BERN
03/21/17
DOWNGRADE
BERN
Underperform
Campbell Soup downgraded to Underperform from Market Perform at Bernstein
03/21/17
BERN
03/21/17
NO CHANGE
BERN
U.S. food companies downgraded to Underperform at Bernstein
Bernstein analyst Alexia Howard downgraded General Mills (GIS), Kellogg (K), J.M. Smucker (SJM), Conagra Brands (CAG), and Campbell Soup (CPB) to Underperform from Market Perform. As reasons for the downgrades, Howard cited the companies' deteriorating revenue trends and her belief that any takeover premiums for the companies " are unlikely to be particularly high." She adds that activist investors probably won't get involved in the stocks while they are trading at such high valuations. Finally, the analyst believes that the companies are being hurt by consumers' desire for fresher foods and unfavorable shelf space trends at retailers. General Mills target to $52 from $61, Campbell target to $54 from $61, J.M. Smucker target to $130 from $147, Kellogg target to $69 from $83, Conagra target remains $36.
05/24/17
PIPR
05/24/17
INITIATION
PIPR
Neutral
Campbell Soup initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Michael Lavery initiated Campbell Soup with a Neutral rating and $59 price target, saying he sees flat 3-year average revenue growth and 4%-5% 3-year average EPS growth, driven mostly by margin expansion.
03/21/17
03/21/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Sprouts Farmers Market (SFM) downgraded to Market Perform at BMO Capital. 2. HubSpot (HUBS) downgraded to Outperform from Strong Buy at Raymond James analyst Terry Tilman saying shares have significantly outperformed year-to-date and recommends taking some profits. 3. MEDNAX (MD) downgraded to Neutral from Outperform at Baird analyst Whit Mayo citing a balanced risk/reward, weak organic growth, its sector high historical and relative EBITDA valuation, and a current setup that appears to be reliant on M&A. 4. Cracker Barrel (CBRL) downgraded to Hold from Buy at Argus with analyst John Staszak saying he expects customer traffic to remain weak and same-store sales growth to decelerate over the next several quarters. 5. Conagra Brands (CAG), Kellogg (K), J.M. Smucker (SJM), General Mills (GIS), and Campbell Soup (CPB) were downgraded to Underperform from Market Perform at Bernstein. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
LVB Steinway Musical
$0.00

(0.00%)

GLW Corning
$31.85

0.14 (0.44%)

04/26/17
UBSW
04/26/17
NO CHANGE
Target $29
UBSW
Neutral
Corning doing better than expected, says UBS
UBS analyst Tejas Venkatesh noted Corning (GLW) beat expectations for Q1 and its guidance surpassed expectations, leading him to say the company is doing better than expected. He also believes the company's deal with Verizon (VZ) is significant, though he maintains his Neutral rating on Corning shares due to currency risk that keeps him on the sidelines. Venkatesh raised his price target to $28.50 from $26 on Corning.
04/19/17
04/19/17
NO CHANGE

Zayo Group has negative read through from Verizon deal, says Pacific Crest
After Verizon (VZ) agreed to buy fiber from Corning (GLW), Pacific Crest analyst Brandon Nispel says the deal indicates that Verizon prefers to build a fiber network on its own instead of leasing one from a third party. The analyst views this development as negative for Zayo which is building and looking to lease fiber networks. He keeps a Sector Weight rating on the stock.
04/19/17
ARGS
04/19/17
NO CHANGE
ARGS
Corning price target raised to $33 from $30 at Argus
Argus analyst Jim Kelleher increased his price target on Corning (GLW) after the company announced a $1.05B fiber supply deal with Verizon (VZ). The analyst says that Corning's valuation is attractive and keeps a Buy rating on the shares.
04/19/17
STFL
04/19/17
NO CHANGE
STFL
Dycom could obtain $300M in revenue from Verizon, says Stifel
After Verizon (VZ) announced a three year agreement to purchase fiber from Corning (GLW), Stifel analyst Noelle Dilts says that Verizon's upcoming deployment of fiber could generate $300M of additional annual revenue for Dycom (DY). The analyst estimates that Verizon's deployment could add 64c to Dycom's annual EPS. She raised her price target on the shares to $120 from $112 and keeps a Buy rating on the stock.
MRK Merck
$62.63

-0.31 (-0.49%)

07/06/17
RHCO
07/06/17
NO CHANGE
RHCO
Hold on Merck Keytruda to have 'limited' impact, says SunTrust
SunTrust analyst John T. Boris says that the FDA's decision to place trials of Merck's Keytruda in multiple myeloma on clinical hold is expected to have a "limited impact" on the drug's near-term and long-term sales. The analyst adds that Merck's upbeat thesis on the drug's outlook "is not materially impacted" by the FDA's decision. He reiterates a $73 price target and a Buy rating on the shares.
06/27/17
06/27/17
NO CHANGE

Large cap pharma could benefit from upcoming executive order, says Wells Fargo
Wells Fargo says that, based on press reports, large cap pharma could benefit from President Trump's upcoming executive order on drug pricing. The firm says the articles indicate that the order will not create major reforms or do anything to lower consumers' costs or solve current pricing issues. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/27/17
BMOC
06/27/17
NO CHANGE
BMOC
Merck Anacetratib data could be positive despite limitations, says BMO Capital
BMO Capital analyst Alex Arfaei says that data on Merck's Anacetratib drug is "a positive surprise," given the failure of two other CEPT inhibitors. But he says that Merck's press release "strongly suggests" that the drug's CV benefit "may not be very clinically meaningful," while the drug's safety issues may prevent it from being worthwhile, given the relative weakness of its efficacy. However, the analyst says that revenue expectations for the drug were a very low $300M by 2020 ,and he now believes that the franchise could generate global sales of $1.5B-$2B. He keeps an Outperform rating on the stock.
07/05/17
SBSH
07/05/17
NO CHANGE
Target $65
SBSH
Neutral
Merck could become market leader in HIV, says Citi
In a research note titled "EFdA - The Remarkable HIV Drug That Could End GILD/ViiV's Dominance," Citi analyst Andrew Baum says he finds it likely that Merck (MRK) could become a market leader in HIV treatment. Given EFdA's profile, Merck intends to develop an oral daily single tablet coformulated with Isentress HD or another oral antiretroviral for HIV-infected patients, Baum tells investors in a research note. He models first EFdA approval as early as 2021 and believes commercial success could add $5B per year to sales forecasts. The analyst keeps a Neutral rating on Merck with a $65 price target.
PFE Pfizer
$33.48

-0.06 (-0.18%)

07/20/17
FBCO
07/20/17
DOWNGRADE
Target $36
FBCO
Neutral
Pfizer downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Vamil Divan downgraded Pfizer to Neutral and lowered his price target for the shares to $36 from $38. The shares closed yesterday up 26c to $33.62. The analyst, who notes he's long been a supporter of Pfizer and continues to see opportunities for upside over the long-term, believes the stock's upside drivers are more limited over the next year. Divan prefers other names in the Major Pharmaceuticals space, such as Johnson & Johnson (JNJ) and Merck (MRK). Growth of Pfizer's Ibrance is slowing while global Prevnar sales are flat to declining, Divan tells investors in a research note. He adds that the company is facing two meaningful patent expirations over the next 18 months with Viagra, Lyrica.
07/14/17
LEER
07/14/17
NO CHANGE
Target $36
LEER
Outperform
Leerink sees significant optionality for AstraZeneca beyond MYSTIC trial
Leerink analyst Seamus Fernandez said he sees significant optionality for AstraZeneca (AZN) beyond the "mega-catalyst" of the MYSTIC trial in non-small cell lung cancer, as he believes several 2017 and 2018 readouts from underappreciated pipeline assets could lead to upside for the shares. If MYSTIC fails, Astra's "massive" SG&A spend gives it flexibility to mute the bottom-line impact. If it is successful, he believes potential acquirers such as Pfizer (PFE) or Novartis (NVS) could see "an attractive target to plunder," Fernandez tells investors. He keeps an Outperform rating and $36 price target on AstraZeneca ADRs.
06/29/17
JEFF
06/29/17
UPGRADE
Target $117
JEFF
Buy
Icon upgraded to Buy from Hold at Jefferies
Jefferies analyst David Windley upgraded Icon (ICLR) to Buy saying the shares continue to trade at a group discount. The analyst sees "solid appreciation potential" as Pfizer (PFE) concentration is reduced and potentially 45% upside with a more aggressive acquisition strategy. The company's management has talked more openly about larger deals, Windley tells investors in a research note. Windley raised his price target for Icon shares to $117 from $86.
07/20/17
07/20/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pfizer (PFE) downgraded to Neutral from Outperform at Credit Suisse with analyst Vamil Divan saying he believes the stock's upside drivers are more limited over the next year. 2. Rite Aid (RAD) downgraded to Neutral from Buy at Mizuho. 3. Fairmount Santrol (FMSA) was downgraded to Sell from Neutral at Goldman Sachs and to Neutral from Outperform at Credit Suisse. 4. New Relic (NEWR) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Sanjit Singh saying shares are up 71% year-to-date and valuation captures solid fundamentals but sees fewer catalysts. 5. Smart Sand (SND) downgraded to Neutral from Outperform at Credit Suisse with analyst James Wicklund saying the regional sand volumes capacity is expanding much faster than had been expected. This drives lower pricing and demand for non-Texas mines, he adds. The analyst also lowered his price target on the shares to $8.50 from $20. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
AMZN Amazon.com
$1,025.67

-3.03 (-0.29%)

07/21/17
RHCO
07/21/17
NO CHANGE
RHCO
Amazon.com, Sears deal doesn't impact Best Buy thesis, says SunTrust
After Best Buy (BBY) dropped following the announcement of a deal between Amazon (AMZN) and Sears (SHLD) on appliances, SunTrust analyst David Magee says the 4% decline in Best Buy's stock is "understandable." However, he says the news doesn't alter his basic thesis on Best Buy. Magee says that Best Buy has shown that it can compete effectively against Amazon in other categories, while there are several other brands of appliances besides Sears' Kenmore that have good reputations and Best Buy will have better service than Sears and Amazon. He keeps a $70 price target and a Buy rating on Best Buy.
07/21/17
JEFF
07/21/17
NO CHANGE
JEFF
Home Depot, Lowe's, Best Buy selloff yesterday overdone, says Jefferies
Jefferies analyst Daniel Binder views the selloff yesterday in shares of Home Depot (HD), Lowe's (LOW) and Best Buy (BBY) on news that Sears (SLD) would sell Alexa-integrated Kenmore appliances through Amazon (AMZN) as overdone. While Amazon shouldn't be underestimated, appliance transactions are complex and Kenmore brand equity has declined, Binder tells investors in a research note. He does not believe the Sears deal is an indicator that more appliance manufacturers will sell direct via Amazon.
07/20/17
JPMS
07/20/17
NO CHANGE
JPMS
Whirlpool pullback on Amazon-Sears team-up overdone, says JPMorgan
JPMorgan analyst Michael Rehaut said he believes the decline in Whirlpool (WHR) following news of Sears' (SHLD) deal to sell appliances via Amazon (AMZN) has been overdone. He notes Whirlpool has proven it can adapt to the changing retail environment and that if Amazon becomes a reasonably large distribution channel for appliances he'd expect the company to participate.
07/20/17
JPMS
07/20/17
NO CHANGE
JPMS
Overweight
Home Depot selloff today overdone, says JPMorgan
JPMorgan analyst Christopher Horvers views the selloff today in Home Depot (HD) shares as overdone. Amazon.com's (AMZN) pact to sell Sears' (SHLD) Kenmore appliances and Sherwin-Williams' (SHW) "disappointing" paint performance is dragging the group down, Horvers tells investors in a research note. He points out that Sherwin-Williams and Valspar house paints sell through Lowe's (LOW), and not Home Depot. Further, Amazon doesn't have a white glove infrastructure for appliances, Horvers says. The analyst recommends buying Home Depot amid today's pullback.
AET Aetna
$156.31

0.58 (0.37%)

06/28/17
SBSH
06/28/17
NO CHANGE
Target $205
SBSH
Buy
Anthem removed from Focus List at Citi
Citi analyst Ralph Giacobbe removed Anthem (ANTM) from his firm's Focus List but keeps a Buy rating on the shares with a $205 price target. The analyst believes some of the upside catalysts have played out. He also added Aetna (AET) to the Focus List.
07/13/17
FBCO
07/13/17
NO CHANGE
Target $165
FBCO
Outperform
Aetna price target raised to $165 from $160 at Credit Suisse
Credit Suisse analyst Scott Fidel raised his price target for Aetna to $165 from $160 ahead of Q2 results. He reiterates an Outperform rating on the shares.
07/14/17
PIPR
07/14/17
NO CHANGE
Target $18
PIPR
Overweight
Piper views updated Aetna policy as disappointing for Natera
Piper Jaffray analyst William Quirk views Aetna's (AET) updated non-invasive prenatal testing medical policy, where it decided to continue covering the test only in high risk, as "disappointing." Upside for Natera (NTRA) in the second half of 2017 now falls on Medicaid and microdeletion reimbursement progress, and less so commercial payers flipping to cover average risk, Quick tells investors in a research note. He keeps an Overweight rating on Natera shares with an $18 price target.
06/28/17
06/28/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Altaba (AABA) initiated with an Overweight at JPMorgan. 2. Aetna (AET) and Humana (HUM) were initiated with a Buy at Citi. The firm also added Aetna to its Focus List. 3. CVS Health (CVS) and Walgreens Boots Alliance (WBA) were initiated with a Hold at Needham. 4. Oaktree Capital (OAK) initiated with a Hold at Jefferies. 5. General Motors (GM) resumed with an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ANTM Anthem
$190.65

-0.04 (-0.02%)

06/23/17
LEER
06/23/17
NO CHANGE
LEER
Outperform
Draft version of Senate healthcare bill better than expected, says Leerink
Leerink analyst Ana Gupte said she views the draft version of the Senate healthcare bill as better than expected, stating that stabilization of the Exchanges and risk stabilization is a direct positive for health insurers and indirect positive for facility operators. The Senate bill maintains the House bill's plan to repeal all "ObamaCare" industry fees and taxes, which is a positive for Managed Care and Medical Technology players, Gupte adds. She keeps Outperform ratings on Anthem (ANTM), UnitedHealth (UNH), Cigna (CI), Humana (HUM), WellCare (WCG), Molina Healthcare (MOH) and acute care hospital operators HCA Holdings (HCA), Tenet (THC) and LifePoint (LPNT).
06/23/17
JEFF
06/23/17
NO CHANGE
JEFF
Jefferies says healthcare rally 'appropriate' after 'toothless' AHCA rewrite
Jefferies analyst David Windley said the rally yesterday in healthcare stocks was appropriate given the "anemic" rewrite of the AHCA healthcare bill by Senate Republicans. The key changes are removal of "pay-for" taxes, a somewhat longer runway for Exchange cost-sharing reduction subsidies, and delayed Medicaid transition to per capita caps, he tells investors. Windley called Cigna (CI) "probably the safest MCO in this noise", adding that Humana (HUM) would benefit most from the proposed removal of the health insurer fee. Other publicly traded healthcare insurers include Aetna (AET), Anthem (ANTM), Centene (CNC), Health Net (HNT), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
07/12/17
FBCO
07/12/17
INITIATION
Target $195
FBCO
Neutral
Anthem initiated with a Neutral at Credit Suisse
Credit Suisse analyst Scott Fidel started Anthem with a Neutral rating and $195 price target. The company has produced slower earnings growth over the past decade relative to Managed Care peers and its returns on capital are also "sub-par relative to comps," the analyst contends. He believes Anthem is "entering a new chapter" following the failed Cigna (CI) acquisition and "uncertain future" of the Affordable Care Act's exchanges and Medicaid expansion.
CNC Centene
$84.73

-0.67 (-0.78%)

05/22/17
05/22/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Momenta (MNTA) downgraded to Equal Weight from Overweight at Barclays with analyst Douglas Tsao citing the likelihood of generic manufacturers, most notably Mylan (MYL), winning approval for generic Copaxone in the coming months. He lowered his price target for the shares to $17 from $20. 2. Zoe's Kitchen (ZOES) downgraded to Neutral from Outperform at Baird with analyst David Tarantino saying he believes the near-term risk profile looks elevated amid signs of sluggish comps for similarly positioned chains and an uptrend in input costs. Tarantino lowered his price target to $20 from $25 on Zoe's Kitchen shares. 3. Arista Networks (ANET) downgraded to Neutral from Buy at DA Davidson with analyst Mark Kelleher citing valuation with the shares up 60% since his initiation in January. 4. Synchronoss (SNCR) downgraded to Underperform from Neutral at Credit Suisse with analyst Michael Nemeroff citing AT&T's (T) recent announcement that it will be closing the personal cloud "Locker" storage service offering powered by Synchronoss on August 3. 5. Centene (CNC) downgraded to Neutral from Overweight at JPMorgan with analyst Gary Taylor citing valuation with the shares up 32% since December 2016. The stock reflects very little probability of Senate Medicaid cuts or block grants, Taylor tells investors in a research note. He keeps a $75 price target for the shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/06/17
MSCO
06/06/17
INITIATION
Target $86
MSCO
Overweight
Centene initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Zack Sopcak initiated Centene with an Overweight and a $86 price target. The analyst thinks the HealthNet acquisition provides diversification and entry planned expansion in Medicare Advantage could offset potential headwinds.
07/11/17
BERN
07/11/17
NO CHANGE
BERN
Centene price target raised to $100 from $85 at Bernstein
Bernstein analyst Lance Wilkes raised his price target on Centene based on his belief that the managed Medicaid market will grow over the long-term, particularly in long-term care. He keeps an Outperform rating on the stock.
CI Cigna
$174.23

-0.26 (-0.15%)

06/16/17
06/16/17
NO CHANGE

Leerink reiterates view that Cigna could bid for Humana
Leerink analyst Ana Gupte reiterated his views that Cigna (CI) could make a bid Humana (HUM) following Cigna's disclosure that 60% of its Medicare Advantage plans will be in 4-STAR rated plans. The announcement is most positive for Humana (HUM) which is the largest pure play Medicare Advantage name, but also paves the way for Cigna to potentially dievest its legacy HS Medicare Advantage book and bid for Humana.
HNT Health Net
$0.00

(0.00%)

11/09/16
BERN
11/09/16
NO CHANGE
BERN
Health insurers to see multiple catalysts from Trump presidency, says Bernstein
Bernstein analyst Lance Wilkes says that "repealing and replacing Obamacare will be Trump's primary focus." The analyst expects health insurers to benefit from from the repeal of ACA taxes and the elimination of requirements to spend a certain percentage of revenue on medical costs. Wilkes expects Anthem (ANTM) and Blue Cross/Blue Shield providers to benefit from the elimination of public exchanges and broad coverage requirements. Other health insurers include Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
HUM Humana
$235.92

0.09 (0.04%)

07/13/17
FBCO
07/13/17
NO CHANGE
Target $250
FBCO
Outperform
Humana price target raised to $250 from $245 at Credit Suisse
Credit Suisse analyst Scott Fidel raised his price target for Humana to $250 from $245 ahead of Q2 results. He reiterates an Outperform rating on the shares.
06/28/17
SBSH
06/28/17
INITIATION
Target $275
SBSH
Buy
Humana initiated with a Buy at Citi
Citi analyst Ralph Giacobbe started Humana with a Buy rating and $275 price target. The company has built a "strong and coveted" Medicare Advantage franchise that should deliver "strong" growth, the analyst contends. He also believes a potential takeout will provide valuation support.
MOH Molina Healthcare
$71.15

-0.9 (-1.25%)

06/14/17
LEER
06/14/17
NO CHANGE
Target $80
LEER
Outperform
Molina Healthcare price target raised to $80 from $70 at Leerink
Leerink analyst Ana Gupte raised her price target for Molina Healthcare shares to $80 and remains "bullish" on the name after a call with CFO and interim CEO Joseph White. The analyst says White aligned with her view that the upcoming re-procurement of State Medicaid contracts "does not pose meaningful downside risk." Further, she learned the CEO search is making good progress with an "attractive slate" of senior executives with Managed Care experience. The analyst keeps an Outperform rating on Molina.
06/06/17
MSCO
06/06/17
INITIATION
Target $65
MSCO
Underweight
Molina Healthcare initiated with an Underweight at Morgan Stanley
Morgan Stanley analyst Zack Sopcak initiated Molina Healthcare with an Underweight and a $65 price target citing premium valuation, uncertainties over management's strategy, and the impact of healthcare reform to Medicaid.
UNH UnitedHealth
$191.78

0.28 (0.15%)

07/19/17
UBSW
07/19/17
NO CHANGE
Target $213
UBSW
Buy
UnitedHealth price target raised to $213 from $194 at UBS
UBS analyst A.J. Rice raised his price target on UnitedHealth to $213 from $194 following Q2 earnings. The analyst cited the company's positive outlook to gain market share in both group and individual Medicare Advantage markets along with continued growth assumptions for Optum Rx. Rice reiterated his Buy rating on UnitedHealth shares.
07/13/17
FBCO
07/13/17
NO CHANGE
Target $200
FBCO
Outperform
UnitedHealth price target raised to $200 from $195 at Credit Suisse
Credit Suisse analyst Scott Fidel raised his price target for UnitedHealth to $200 from $195 ahead of Q2 results. He reiterates an Outperform rating on the shares.
06/27/17
KEYB
06/27/17
DOWNGRADE
KEYB
Sector Weight
LabCorp downgraded on potential acquisition at KeyBanc
As noted earlier, KeyBanc downgraded LabCorp to Sector Weight from Overweight. Analyst Donald Hooker downgraded the stock based on his belief that the company implied that it may make an "expensive" deal to acquire a contract research organization. The analyst adds that the upcoming renewal of the company's contract with UnitedHealth (UNH) in 2H18 creates uncertainty.He expects to hear news about the deal "in coming months."
WCG WellCare
$183.87

0.1 (0.05%)

07/13/17
FBCO
07/13/17
NO CHANGE
Target $163
FBCO
Neutral
WellCare price target raised to $163 from $155 at Credit Suisse
Credit Suisse analyst Scott Fidel raised his price target for WellCare to $163 from $155 ahead of Q2 results. He reiterates a Neutral rating on the shares.
06/06/17
MSCO
06/06/17
INITIATION
Target $183
MSCO
Equal Weight
WellCare initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Zack Sopcak initiated WellCare with an Equal Weight rating and $183 price target, citing its current valuation.
X U.S. Steel
$23.68

-0.47 (-1.95%)

07/03/17
BMOC
07/03/17
NO CHANGE
BMOC
Steel stocks still have positive risk/reward ratio, says BMO Capital
BMO Capital analyst David Gagliano says that "during the past two weeks, the majority of the steel lead-indicators we monitor have either stabilized or started to move higher." He adds that the Trump administration may levy tariffs which will cause imports to drop significantly over the next three to six months. As a result, the analyst believes that the steel stocks "continue to provide a favorable risk/reward opportunity." Publicly traded steel stocks include AK Steel (AKS), United States Steel (X), Nucor Corporation (NUE), and Steel Dynamics (STLD).
07/13/17
MSCO
07/13/17
NO CHANGE
MSCO
Morgan Stanley says its time to buy Steels
Morgan Stanley analyst Evan Kurtz met with steel executives last night and came away more bullish on potential second half 2017 pricing strength. Kurtz said steel buyers have been keeping inventories low given the uncertainty of the 232 investigation and he expects imports to drop sharply in September and October as importers likely look to reduce risk from potential 232 penalties ahead. The analyst said demand appears steady and many steel buyers have yet to complete Q3 purchases, and he expects scrap to remain stable near-term. Kurts believes Overweight rated U.S. Steel (X), Steel Dynamics(STLD), and Nucor (NUE) could be strong second half performers given positioning and leverage.
07/18/17
MSCO
07/18/17
NO CHANGE
MSCO
Morgan Stanley more bullish on second half steel pricing
Following a dinner with steel participants last week, Morgan Stanley analyst Evan Kurtz said he is more bullish on second half 2017 steel pricing. The takeaways were that imports are likely to dip significantly in September and October due to traders not wanting to take the risk of being an "import of record" with the threat of tariffs. Further, the analyst said inventories are low, so even with stable demand, the market could get tight, the analyst wrote. Kurtz raised his HRC forecast for the second half to $625/st from $570/st, and raised his scrap forecast by $30/t. The analyst recommends buying Overweight rated U.S. Steel (X), Steel Dynamics (STLD) and Nucor (NUE).
07/20/17
07/20/17
NO CHANGE

Cowen would be buying Steel stock weakness
Cowen said the lackluster earnings from Steel Dynamics (STLD) and Nuecor (NUE) is causing weakness in the steel sector. The firm's analyst would use the weakness to buying opportunity given the reports are backwards looking, HRC prices are moving higher, service center inventories are low, and an announcement on steel tariffs is imminent. The firm would not want to be short the group and reiterates outperform ratings on TimkenSteel (TMST) and Steel Dynamics
STLD Steel Dynamics
$37.51

-0.18 (-0.48%)

NUE Nucor
$60.23

0.31 (0.52%)

CYH Community Health
$9.27

0.01 (0.11%)

05/31/17
PIPR
05/31/17
NO CHANGE
PIPR
Piper raises 'early caution flag' for Q2 hospital earnings
Following her firm's May outpatient survey, Piper Jaffray analyst Sarah James is putting up an "early caution flag" for Q2 hospital earnings. The May outpatient survey indicates April was the peak, declining in May, with indications that June could be below April as well, James tells investors in a research note. After four months of increases, the outpatient survey declined 50 basis points from the April peak to 2.5% year-over-year same-hospital admissions in May, the analyst adds. She views the decline as concerning amid "tenuous" investor sentiment and "optimistic" Q2 expectations. Hospitals that Piper covers include Community Health (CYH), HCA Holdings (HCA), LifePoint (LPNT), Tenet (THC) and Universal Health (UHS).
06/06/17
MSCO
06/06/17
INITIATION
Target $10
MSCO
Underweight
Community Health initiated with an Underweight at Morgan Stanley
Morgan Stanley analyst Zack Sopcak initiated Community Health with an Underweight and a $10 price target citing valuation and said he sees downside if there are not more signs of a turnaround.
07/13/17
BARD
07/13/17
NO CHANGE
Target $10
BARD
Neutral
Community Health Q2 estimates seem too high, says Baird
Baird analyst Whit Mayo said his detailed look into the Community Health inpatient hospital records in Florida show material declines in volumes, market share and reputation. He now believes Q2 estimates may be too high and guidance carries a downward bias. Mayo is maintaining his cautious stance, Neutral rating and $10 price target on Community Health shares.
04/05/17
DBAB
04/05/17
INITIATION
Target $11
DBAB
Hold
Community Health initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Chris Rigg started Community Health Systems with a Hold rating and $11 price target.
HCA HCA Healthcare
$85.73

-0.03 (-0.03%)

06/28/17
ARGS
06/28/17
INITIATION
ARGS
Buy
HCA Holdings initiated with a Buy at Argus
Argus analyst Stephen Biggar started coverage of HCA with a $100 price target and a Buy rating. He expects HCA to benefit from small increases in demand and average revenue per admission this year. The analyst expects the company's revenue growth to accelerate next year due to "slightly better demand trends and a small improvement in payor mix." He predicts that the company's margins will rise slightly in 2018, driven by cost controls and more favorable customer mix.
06/06/17
LEER
06/06/17
UPGRADE
LEER
Outperform
HCA Holdings upgraded to Outperform from Market Perform at Leerink
06/07/17
LEER
06/07/17
UPGRADE
LEER
Outperform
Leerink upgrades hospitals HCA, LifePoint, Tenet to Outperform
Leerink analyst Ana Gupte last night upgraded hospitals HCA Holdings (HCA), LifePoint (LPNT) and Tenet healthcare (THC) to Outperform from Market Perform. She raised her price target for HCA to $100 from $90, for LifePoint to $74 from $73 and maintains a $27 price target for HCA. The targets offer upside of 21%, 20% and 62% respectively. Anthem's (ANTM) announced exit yesterday from the key swing state of Ohio's healthcare exchange could bring further attention to the need for stabilization funding through legislation, Gupte tells investors in a research note. She believes improving policy under the Trump Administration could drive upside to 2018 and 2019 consensus estimates. Further, the analyst thinks medium term downside risk from Republican's repeal and replace healthcare bill is likely better than feared as publicly traded hospitals are "heavily weighted to non-expansion states," which lessons the impact of Medicaid expansion funding cuts.
LPNT LifePoint
$65.35

-0.15 (-0.23%)

06/06/17
MSCO
06/06/17
INITIATION
Target $65
MSCO
Equal Weight
LifePoint initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Zack Sopcak initiated LifePoint with an Equal Weight rating and $65 price target, citing volume and price pressures on the hospital industry expected over the next several years.
06/06/17
LEER
06/06/17
UPGRADE
LEER
Outperform
LifePoint upgraded to Outperform from Market Perform at Leerink
THC Tenet
$20.65

-0.02 (-0.10%)

06/07/17
06/07/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Ormat Technologies (ORA) upgraded to Overweight from Neutral at JPMorgan with analyst Paul Coster saying he believes the company is well positioned to continue posting revenue growth and margin expansion over the next few years. 2. Tenet (THC) upgraded to Outperform from Market Perform at Leerink. 3. Cott Corp. (COT) and Dr Pepper Snapple (DPS) were upgraded to Outperform from Market Perform at BMO Capital. 4. Sun Life Financial (SLF) upgraded to Outperform from Sector Perform at RBC Capital with analyst Darko Mihelic saying net flows and Assets Under Management at the company's MFS unit have improved over the last two months. He also notes that the stock has fallen about 12% since February. 5. Valvoline (VVV) upgraded to Buy from Neutral at Seaport Global with analyst Michael Harrison saying he expects the oil market to return to looser supply/demand and pricing to decline in the summer once Motiva completes its Port Arthur, TX turnaround in June, which would be a positive for Valvoline margins. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/06/17
LEER
06/06/17
UPGRADE
LEER
Outperform
Tenet upgraded to Outperform from Market Perform at Leerink
UHS Universal Health
$124.42

-0.58 (-0.46%)

03/27/17
03/27/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Adobe (ADBE) upgraded to Buy from Neutral at BTIG. 2. Best Buy (BBY) upgraded to Overweight from Neutral at Piper Jaffray with analyst Peter Keith saying store closures from hhgregg and potentially Sears (SHLD) could lift Best Buy's comp sales by 2%, Keith tells investors in a research note. Further, the upcoming iPhone and Samsung Galaxy Note launches should bring a "strong smartphone upgrade cycle," the analyst contends. 3. HCA Holdings (HCA) and Universal Health (UHS) were upgraded to Buy from Neutral at Mizuho. 4. Weatherford (WFT) upgraded to Outperform from Market Perform at Wells Fargo with analyst Judson Bailey citing greater confidence in improving operations with the hire of CEO Mark McCollum and the formation of the OneStim joint venture. 5. Brookdale Senior Living (BKD) upgraded to Buy from Hold at Jefferies with analyst Brian Tanquilut citing an improved risk/reward following the recent pullback in the shares. The analyst sees a greater than 50% probability that Brookdale's ongoing sale process results in a deal, but thinks the stock can reach $14.50 even without a takeout. He upped his price target for the shares to $16.50 from $14. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/06/17
MSCO
06/06/17
INITIATION
Target $124
MSCO
Equal Weight
Universal Health initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Zack Sopcak initiated Universal Health with an Equal Weight rating and $124 price target, citing volume and price pressures on the hospital industry expected over the next several years.
04/04/17
DBAB
04/04/17
INITIATION
DBAB
Buy
Universal Health initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Chris Rigg initiated Universal Health with a Buy rating and a $145 price target, citing the company's long-term track record and "pristine" balance sheet.

TODAY'S FREE FLY STORIES

GS

Goldman Sachs

$193.29

1.95 (1.02%)

11:55
11/21/18
11/21
11:55
11/21/18
11:55
Periodicals
Abu Dhabi fund sues Goldman Sachs over 1MDB scandal, FT says »

Abu Dhabi's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KNHBF

ICC International Cannabis

$0.00

(0.00%)

, CGC

Canopy Growth

$34.08

2.17 (6.80%)

11:51
11/21/18
11/21
11:51
11/21/18
11:51
OnTheFly
Rising High: International Cannabis agrees to acquire Green Gene »

Welcome to "Rising High,"…

KNHBF

ICC International Cannabis

$0.00

(0.00%)

CGC

Canopy Growth

$34.08

2.17 (6.80%)

MMNFF

MedMen

$0.00

(0.00%)

ACB

Aurora Cannabis

$6.27

0.23 (3.81%)

CVSI

CV Sciences

$0.00

(0.00%)

CNTTF

CannTrust Holdings

$0.00

(0.00%)

CRON

Cronos Group

$8.57

0.38 (4.64%)

CANN

General Cannabis

$0.00

(0.00%)

IGC

India Globalization Capital

$0.00

(0.00%)

TLRY

Tilray

$107.50

3.56 (3.43%)

MLCPF

MediPharm Labs

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

CRM

Salesforce

$124.33

3.61 (2.99%)

11:50
11/21/18
11/21
11:50
11/21/18
11:50
Options
Put spread in Salesforce as shares bounce 3% »

Put spread in Salesforce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 27

    Nov

  • 28

    Nov

  • 29

    Nov

  • 06

    Dec

  • 11

    Dec

  • 03

    Mar

11:45
11/21/18
11/21
11:45
11/21/18
11:45
General news
Treasury's $11 B 10-year TIPS reopening was ok »

Treasury's $11 B…

11:45
11/21/18
11/21
11:45
11/21/18
11:45
General news
Atlanta Fed's Q4 GDPNow estimate was unchanged at 2.5% »

Atlanta Fed's Q4…

11:45
11/21/18
11/21
11:45
11/21/18
11:45
General news
Breaking General news story  »

Week of 11/16 EIA Natural…

AQST

Aquestive Therapeutics

$9.60

-3.57 (-27.11%)

, RDY

Dr. Reddy's

$36.89

0.41 (1.12%)

11:44
11/21/18
11/21
11:44
11/21/18
11:44
Recommendations
Aquestive Therapeutics, Dr. Reddy's analyst commentary  »

Aquestive selloff on…

AQST

Aquestive Therapeutics

$9.60

-3.57 (-27.11%)

RDY

Dr. Reddy's

$36.89

0.41 (1.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

HIG

Hartford Financial

$44.70

0.6 (1.36%)

11:40
11/21/18
11/21
11:40
11/21/18
11:40
Options
Higher option volume in Hartford fueled by call buying »

Higher option volume in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

11:36
11/21/18
11/21
11:36
11/21/18
11:36
General news
10-Yr TIPS Auction Coupon Rate data reported »

10-Yr TIPS Auction Coupon…

11:36
11/21/18
11/21
11:36
11/21/18
11:36
General news
10-Yr TIPS Auction Total Amount data reported »

10-Yr TIPS Auction Total…

11:35
11/21/18
11/21
11:35
11/21/18
11:35
General news
Treasury announced a $111 B package of short dated coupons auctions for next week »

Treasury announced a $111…

BECN

Beacon Roofing

$32.97

4.9 (17.46%)

11:32
11/21/18
11/21
11:32
11/21/18
11:32
Upgrade
Beacon Roofing rating change  »

Beacon Roofing upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

PCG

PG&E

$24.20

0.64 (2.72%)

11:30
11/21/18
11/21
11:30
11/21/18
11:30
Options
2K PG&E Mar 28 - 33 call spreads bought for $1.58 »

2K PG&E Mar 28 - 33…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:25
11/21/18
11/21
11:25
11/21/18
11:25
General news
Treasury's 10-year TIPS preview: the $11 B reopening may be weakened »

Treasury's 10-year…

AMD

AMD

$19.24

0.04 (0.21%)

11:20
11/21/18
11/21
11:20
11/21/18
11:20
Options
Sweep buyers of AMD weekly puts »

Sweep buyers of AMD…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 06

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
11/21/18
11/21
11:17
11/21/18
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
11/21/18
11/21
11:16
11/21/18
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYAD

Celyad

$26.97

(0.00%)

, BLUE

Bluebird Bio

$116.82

0.55 (0.47%)

11:11
11/21/18
11/21
11:11
11/21/18
11:11
Conference/Events
William Blair biotech analysts to hold an analyst/industry conference call »

Biotech Analysts, along…

CYAD

Celyad

$26.97

(0.00%)

BLUE

Bluebird Bio

$116.82

0.55 (0.47%)

NVS

Novartis

$88.49

1.51 (1.74%)

GILD

Gilead

$67.04

-0.54 (-0.80%)

CELG

Celgene

$67.69

0.93 (1.39%)

AUTL

Autolus Therapeutics

$42.60

1.4 (3.40%)

ALLO

Allogene Therapeutics

$26.40

0.79 (3.08%)

CLLS

Cellectis

$20.89

0.65 (3.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 27

    Nov

  • 27

    Nov

  • 29

    Nov

  • 01

    Dec

  • 02

    Dec

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

  • 03

    Dec

  • 10

    Dec

  • 13

    Dec

11:10
11/21/18
11/21
11:10
11/21/18
11:10
General news
2-Yr FRN Note Announcement CUSIP Number data reported »

2-Yr FRN Note…

11:10
11/21/18
11/21
11:10
11/21/18
11:10
General news
2-Yr FRN Note Announcement Offering Amount data reported »

2-Yr FRN Note…

11:10
11/21/18
11/21
11:10
11/21/18
11:10
General news
7-Yr Note Announcement CUSIP Number data reported »

7-Yr Note Announcement…

11:10
11/21/18
11/21
11:10
11/21/18
11:10
General news
7-Yr Note Announcement Offering Amount data reported »

7-Yr Note Announcement…

11:10
11/21/18
11/21
11:10
11/21/18
11:10
General news
5-Yr Note Announcement CUSIP Number data reported »

5-Yr Note Announcement…

11:10
11/21/18
11/21
11:10
11/21/18
11:10
General news
5-Yr Note Announcement Offering Amount data reported »

5-Yr Note Announcement…

11:10
11/21/18
11/21
11:10
11/21/18
11:10
General news
2-Yr Note Announcement CUSIP Number data reported »

2-Yr Note Announcement…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.